Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Clin Lung Cancer

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Science, Guangzhou, China. Electronic address:

Published: March 2015

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.cllc.2014.11.001	DOI Listing

Publication Analysis

lung adenocarcinoma

adenocarcinoma harboring

harboring concomitant

concomitant egfr

egfr mutation

mutation eml4-alk

eml4-alk fusion

fusion benefits

benefits three

three kinds

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!